Dr Reddy’s share price jumps 4% on Nuvama’s upgrade to buy; brokerage sees potential despite risks from Revlimid expiry
Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...
Dr Reddy's shares rally 4% as Nuvama upgrades rating to buy
Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...
ndtvprofit18h
Nuvama's Top Picks In Retail Space: Titan, Jubilant Foodworks, Aditya Vision, VMart And More
The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...
45 companies could report double-digit profit slump in Q3. Are your stocks on this list?
India Inc. is bracing for mixed Q3 results, with earnings growth expected to slow. Analysts predict a 2% Nifty EPS growth for ...
ndtvprofit1h
Stock Recommendations Today: Swiggy, Bajaj Auto, Tata Motors On Brokerages' Radar
CLSA revised its rating for Bajaj Auto Ltd.'s share price to 'outperform' from 'underperform' earlier, after recent ...
Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...
Dr Reddy's surges 4% on Nuvama upgrade to 'buy', bullishness on efforts to mitigate Revlimid expiry impact
Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.
Nifty earnings to slow down in Q3FY25 will lead to heightened market volatility in 2025: Nuvama Research
The report said "Nifty EPS is likely to grow 2 per cent (versus 4 per cent in H1FY25)-posing downgrade risks to H2FY25 consensus estimate of mid-teens growth".
Nomura, Nuvama say 'Buy' SBI Card shares; upgrade stock on these reasons
Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...